Erhalte eine Antwort von diesem Arbeitgeber
Dein Lebenslauf und dein Anschreiben, genau auf das zugeschnitten, was gesucht wird.
DBV Technologies in Warren, NJ seeks a Senior Director of Biostatistics to lead statistical strategy for Medical Affairs and emerging Commercial activities as VIASKIN Peanut progresses toward U.S. launch.
The role sits within Biometrics, enabling access to analysis datasets and ensuring alignment with regulatory standards, while serving Medical Affairs, Medical Information, and Commercial teams to craft credible, data-driven messaging.
Reporting to the Vice President, Biostatistics, the Senior Director of Biostatistics will serve as the dedicated statistical lead supporting DBV's Medical Affairs and emerging Commercial organizations as the company advances VIASKIN® Peanut through BLA submission and prepares for U.S. commercial launch. While based within the Biometrics function — ensuring direct access to analysis datasets, consistency with regulatory analyses, and shared statistical standards — this role's mandate and customers sit outside it: Medical Affairs, Medical Information, and Commercial. A dotted-line relationship to the Head of Medical Affairs (or CMO) formalizes that accountability.
The role owns the statistical dimension of DBV's externally facing medical and commercial evidence work: generating the post-hoc, subgroup, integrated, and descriptive analyses Medical Affairs needs for scientific exchange and launch readiness; serving as the statistical authority behind Medical Information deliverables; providing statistical support to publications and congress activity led by Medical Affairs colleagues; and — critically — owning statistical substantiation of approved, branded messaging as DBV builds its first promotional review infrastructure. This is deliberately not a trial-execution role: SAPs, CSRs, and BLA analyses remain with the broader Biometrics team and CRO partners. The role exists so that launch-critical medical and commercial analytics are not competing with regulatory deliverables for the same statistician.
In a first-in-class category (epicutaneous immunotherapy) with a pediatric population and no comparator precedent, the line between what the data shows and what the organization wants to say will be tested constantly. Sitting in Biometrics gives this leader the institutional independence to hold that line in medical/legal/regulatory (MLR) review and claims-development settings, while day-to-day embedding with Medical and Commercial ensures they help those teams find the strongest messages the evidence genuinely supports.
The successful candidate will have done this before: supported publications and congress activity as the statistician, fielded the statistical side of medical information, and worked shoulder-to-shoulder with a commercial organization through a launch — turning pivotal-trial data into claims grids, substantiation packages, and launch materials that survived legal, regulatory, and competitive scrutiny. They will operate hands-on in a lean environment, often as the only statistician in the room.
Warren, New Jersey - minimum 3 days on site, with domestic and occasional international travel as required (congresses; coordination with Châtillon, France HQ).
$240-280k
DBV Technologies is a global clinical stage biopharmaceutical company founded by pediatricians who believed that food allergies could one day be treated safely and effectively.
We are on a mission to advance epicutaneous immunotherapy using our innovative technology platform, Viaskin™, to develop treatment options for immunologic diseases with significant unmet medical need.
This mission drives our commitment to the advancement of treatments for patients and their families. That is why we are investigating a potential new class of immunotherapy, epicutaneous immunotherapy (EPIT), that aims to re-educate the immune system of patients through the skin.
Today, we are focused on exploring the use of Viaskin to address food allergies, a devastating condition that afflicts millions of patients. As an important milestone in our journey, we hope to offer the first epicutaneous immunotherapy treatment for peanut allergy.
Tomorrow, as pioneers, we will continue to explore the broad applications of this potential new class of immunotherapy, including treatments for patients suffering from inflammatory and autoimmune diseases.